We found that miR-129 overexpression reduced CP110 expression at both the mRNA and protein level, whereas transfection of the miR-129-3p inhibitor increased CP110 expression in breast cancer cells (Fig. 2D–G). Here, CCP110 is linked to breast carcinoma.